BRIEF-Invion Secures Non-Dilutive Funding From Hanlim Pharm And Korean Government Research Fund

BUZZ-Australia's Immutep hits 15-month high on positive IMP761 trial update

Biotron Ltd-Director Appointment DR Paul Kasian & Appendix 3X

Paradigm Biopharmaceuticals Moves to Reach Patient Recruitment Milestone in Phase 3 Knee Osteoarthritis Trial

Invion Ltd - Work Program Estimated to Be Worth up to a$2 Mln

Invion Ltd - Non-Dilutive Funding Secured From Hanlim Pharm and Korean Govt Research Fund for Esophageal Cancer Preclinical Program

Opthea Limited Issues New Options to Directors Under NED Plan

Asian Equities Traded in the US as American Depositary Receipts Rise in Monday Trading

Immutep Announces Positive Update on Imp761, a First-in-Class Lag-3 Agonist Antibody for Autoimmune Diseases, From Phase I Study

Immutep Ltd - Trial to Continue With Updates Expected in 1H Cy2026

Immutep Ltd - Dose Dependent Immunosuppressive Effect Observed With Safety Profile

BUZZ-Australia's Dimerix hits 7-month high on $4.8 billion sale

Mayne Pharma Group Says Net Revenues Fall 5.5% Year on Year for the Period Between July, November

BRIEF-Neuren Pharmaceuticals Says Health Canada Approves Clinical Trial Application For NNZ-2591

BRIEF-Mayne Pharma Says Net Revenues Were A$165 Million For First 5 Months Of FY26

Immutep Completes Two Dosing Levels in Single-Ascending Dose Portion of Phase 1 Autoimmune Disease Trial

BUZZ-Australia's Neuren Pharma climbs after Canada approves drug trial

Dimerix Agrees to Acquire US Licensing Partner for Nearly $5 Billion

Neuren Pharmaceuticals Ltd - Health Canada Approves Clinical Trial Application for Nnz-2591